Literature DB >> 25054891

Bevacizumab therapy for glioblastoma: a passionate discussion.

Annick Desjardins1, Henry S Friedman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25054891      PMCID: PMC6128197          DOI: 10.2217/cns.13.53

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


× No keyword cloud information.
  9 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

2.  Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; John P Kirkpatrick; David A Reardon; Katherine B Peters; James E Herndon; Jennifer Marcello; Leighann Bailey; Stevie Threatt; John Sampson; Allan Friedman; Henry S Friedman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-30       Impact factor: 7.038

3.  Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.

Authors:  W B Pope; Q Xia; V E Paton; A Das; J Hambleton; H J Kim; J Huo; M S Brown; J Goldin; T Cloughesy
Journal:  Neurology       Date:  2011-02-01       Impact factor: 9.910

4.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.

Authors:  Albert Lai; Anh Tran; Phioanh L Nghiemphu; Whitney B Pope; Orestes E Solis; Michael Selch; Emese Filka; William H Yong; Paul S Mischel; Linda M Liau; Surasak Phuphanich; Keith Black; Scott Peak; Richard M Green; Cynthia E Spier; Tatjana Kolevska; Jonathan Polikoff; Louis Fehrenbacher; Robert Elashoff; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

5.  Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jeannette M Dowell; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; Melissa Wagner; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

6.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

7.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors:  A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal:  Neurology       Date:  2008-03-04       Impact factor: 9.910

8.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

9.  Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.

Authors:  D A Reardon; J E Herndon; K B Peters; A Desjardins; A Coan; E Lou; A L Sumrall; S Turner; E S Lipp; S Sathornsumetee; J N Rich; J H Sampson; A H Friedman; S T Boulton; D D Bigner; H S Friedman; J J Vredenburgh
Journal:  Br J Cancer       Date:  2012-10-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.